erlotinib hydrochloride has been researched along with lenvatinib in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (lenvatinib) | Trials (lenvatinib) | Recent Studies (post-2010) (lenvatinib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 975 | 112 | 946 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | lenvatinib (IC50) |
|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.0162 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.039 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.051 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.022 | |
| Kinesin-1 heavy chain | Homo sapiens (human) | 0.01 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.0052 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0035 | |
| Nuclear receptor coactivator 4 | Homo sapiens (human) | 0.01 | |
| Coiled-coil domain-containing protein 6 | Homo sapiens (human) | 0.01 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chuma, M; He, X; Hikiba, Y; Kanemaru, Y; Maeda, S; Nakamori, Y; Nozaki, A; Sato, T; Sugimori, M; Suzuki, Y | 1 |
| Chen, Y; Dong, Q; Fu, Y; Hu, B; Li, J; Li, TE; Qin, LX; Qin, W; Ren, X; Shen, X; Su, Y; Sun, H; Wang, CQ; Wang, S; Wang, X; Wang, Z; Zhang, Z; Zheng, Y; Zhu, L; Zou, T | 1 |
| Li, S; Liu, Q; Peng, Y; Qin, S; Tan, C; Wan, X; Wang, L; Zeng, X | 1 |
3 other study(ies) available for erlotinib hydrochloride and lenvatinib
| Article | Year |
|---|---|
EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Reactive Oxygen Species | 2022 |
Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; STAT3 Transcription Factor; Tyrosine | 2022 |
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Quality-Adjusted Life Years; Sorafenib; Sunitinib | 2023 |